Literature DB >> 17100765

In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with Wegener's granulomatosis.

A-I Kälsch1, W H Schmitt, A Breedijk, S Marinaki, S Weigerding, T C Nebe, K Nemoto, F J van der Woude, B A Yard, R Birck.   

Abstract

15-Deoxyspergualin (DSG) is an alternative treatment modality for Wegener's granulomatosis (WG) patients refractory to conventional treatment. Nevertheless, it is unclear how DSG modulates disease activity in these patients. This study was conducted to investigate which parameters of adaptive and acquired immunity were influenced during two subsequent cycles of DSG treatment. Emphasis was put upon T cell and monocyte activation, neutrophil function and surface expression of proteinase-3 (PR-3). Anti-CD3/anti-CD28 and interleukin (IL)-15/IL-7-mediated T cell proliferation were assessed by fluorescence activated cell sorter (FACS) analysis using carboxyfluorescein succinimidyl ester (CSFE) labelling. Interferon (IFN)-gamma and IL-10 production were determined in the supernatants of these cultures by enzyme-linked immunosorbent assay. Monocyte activation was assessed in lipopolysaccharide (LPS)-stimulated whole blood, using tumour necrosis factor (TNF)-alpha as read-out. Neutrophil function was determined by measuring oxidative burst, chemotaxis and phagocytosis. T cell activation markers and PR3 expression were measured by FACS. All parameters were determined directly before and after each DSG cycle. Anti-CD3/anti-CD28-mediated T cell proliferation was reduced directly after DSG treatment. Directly before a subsequent cycle of DSG was started, T cell proliferation was increased. Similar findings were observed for IFN-gamma and IL-10 production by T cells. DSG did not influence IL-15/IL-7-mediated T cell proliferation. LPS-mediated TNF-alpha production was also impaired directly after DSG treatment. No influence on T cell activation markers, neutrophil function and surface PR-3 expression was observed in peripheral blood of these patients. Our data demonstrate that DSG influences T cell and monocyte activation in a reversible fashion. Although DSG causes neutropenia in these patients, it does not influence neutrophil function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100765      PMCID: PMC1810421          DOI: 10.1111/j.1365-2249.2006.03231.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.

Authors:  M Vockerodt; H Tesch; D Kube
Journal:  Genes Immun       Date:  2001-12       Impact factor: 2.676

2.  Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener's granulomatosis.

Authors:  Saskia Vogt; Christof Iking-Konert; Friederike Hug; Konrad Andrassy; G Maria Hänsch
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

3.  In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-kappaB activation.

Authors:  Michael L Diegel; Steven G Nadler; Peter A Kiener
Journal:  Int Immunopharmacol       Date:  2002-09       Impact factor: 4.932

4.  Phorbol myristate acetate induces neutrophil NADPH-oxidase activity by two separate signal transduction pathways: dependent or independent of phosphatidylinositol 3-kinase.

Authors:  A Karlsson; J B Nixon; L C McPhail
Journal:  J Leukoc Biol       Date:  2000-03       Impact factor: 4.962

5.  Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells.

Authors:  J Z Qin; J Kamarashev; C L Zhang; R Dummer; G Burg; U Döbbeling
Journal:  J Invest Dermatol       Date:  2001-09       Impact factor: 8.551

6.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

7.  15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.

Authors:  Rainer Birck; Klaus Warnatz; Hanns M Lorenz; Mira Choi; Marion Haubitz; Mathias Grünke; Hans H Peter; Joachim R Kalden; Ursula Göbel; Johannes M Drexler; Osamu Hotta; Rainer Nowack; Fokko J Van Der Woude
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

Review 8.  The Th1 and Th2 paradigm in ANCA-associated vasculitis.

Authors:  J S F Sanders; C A Stegeman; C G M Kallenberg
Journal:  Kidney Blood Press Res       Date:  2003       Impact factor: 2.687

9.  Lymphopenia in Wegener's granulomatosis. A new clinical activity index?

Authors:  Hassane Izzedine; Patrice Cacoub; Vincent Launay-Vacher; Corinne Bagnis; Gilbert Deray
Journal:  Nephron       Date:  2002-10       Impact factor: 2.847

10.  The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation.

Authors:  Hilda Holcombe; Ira Mellman; Charles A Janeway; Kim Bottomly; Bonnie N Dittel
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

View more
  5 in total

Review 1.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 2.  ANCA-associated vasculitis: from bench research to novel treatments.

Authors:  Lalit Pallan; Caroline O Savage; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

Review 3.  Pharmacological targeting of the Hsp70 chaperone.

Authors:  Srikanth Patury; Yoshinari Miyata; Jason E Gestwicki
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 4.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

Authors:  A-I Kälsch; M Soboletzki; W H Schmitt; F J van der Woude; A Hochhaus; B A Yard; R Birck
Journal:  Clin Exp Immunol       Date:  2008-01-10       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.